Generic Drug-Focused Amneal Beats Q3 Expectations, Reaffirms Annual Forecasts

Published on 8 Nov 2024 on Benzinga · via Yahoo Finance

On Friday, Amneal Pharmaceuticals Inc (NASDAQ:AMRX) reported third-quarter adjusted EPS of $0.16,...

Read the rest of the article

Start tracking your investments with Statfolio

Release Date: November 08, 2024 For the complete transcript of the earnings call, please refer to...

GuruFocus.com · via Yahoo Finance 10 Nov 2024

On Friday, Amneal Pharmaceuticals Inc (NASDAQ:AMRX) reported third-quarter adjusted EPS of $0.16,...

Benzinga · via Yahoo Finance 8 Nov 2024

Amneal Pharmaceuticals Inc (NASDAQ:AMRX) is set to release its Q3 2024 earnings on Nov 8, 2024. T...

GuruFocus.com · via Yahoo Finance 7 Nov 2024

Q2 Revenue: $702 million, a growth of 17%. Generics Net Revenue: $427 million, up 14%. Biosimilar...

GuruFocus.com · via Yahoo Finance 11 Oct 2024

The transaction was documented in a recent SEC Filing. Following this sale, the insider now owns...

GuruFocus.com · via Yahoo Finance 24 Aug 2024

Following this transaction, the insider now owns 256,670 shares of Amneal Pharmaceuticals Inc....

GuruFocus.com · via Yahoo Finance 8 Aug 2024

On May 17, 2024, Deborah Autor, Director at Amneal Pharmaceuticals Inc (NASDAQ:AMRX), executed a ...

GuruFocus.com via Yahoo Finance 22 May 2024

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Q1 2024 Earnings Call Transcript May 3, 2024 Amneal Phar...

Insider Monkey via Yahoo Finance 4 May 2024

, opens new tab said on Friday it had reached a deal valued at more than $270 million to resolve...

Reuters 3 May 2024

Amneal (AMRX) stock climbed 9% Friday after the drugmaker released its Q1 earnings report and sai...

Seeking Alpha 3 May 2024